Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.17
Nov 17 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
120.80M
Enterprise Value
36.41M
Income
-27.98M
Sales
34.37M
Book/sh
1.46
Cash/sh
0.98
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
91
IPO
Dec 05, 2019
P/E
-
Forward P/E
-
PEG
-
P/S
3.51
P/B
0.80
P/C
1.19
P/FCF
-
EV/EBITDA
-
EV/Sales
1.06
Quick Ratio
7.37
Current Ratio
7.83
Debt/Eq
0.11
LT Debt/Eq
0.10
Option/Short
Yes / Yes
EPS (ttm)
-0.26
EPS next Y
-0.23
EPS next Q
-0.07
EPS this Y
39.11%
EPS next Y
10.54%
EPS next 5Y
22.67%
EPS past 3/5Y
-21.85% -19.78%
Sales past 3/5Y
-9.30% 4.76%
EPS Y/Y TTM
38.72%
Sales Y/Y TTM
-0.13%
EPS Q/Q
60.52%
Sales Q/Q
48.66%
Insider Own
8.12%
Insider Trans
0.00%
Inst Own
62.59%
Inst Trans
-2.27%
ROA
-14.13%
ROE
-16.90%
ROIC
-16.83%
Gross Margin
69.70%
Oper. Margin
-78.98%
Profit Margin
-81.40%
SMA20
-14.94%
SMA50
-6.28%
SMA200
9.18%
Trades
Shs Outstand
103.23M
Shs Float
94.86M
52W High
1.80 -35.18%
52W Low
0.64 81.85%
Volatility
11.16% 11.71%
ATR (14)
0.13
RSI (14)
42.01
Beta
1.54
Rel Volume
0.00
Avg Volume
1.00M
Volume
0
Perf Week
3.54%
Perf Month
-10.00%
Perf Quarter
-15.83%
Perf Half Y
12.50%
Perf YTD
-24.52%
Perf Year
-28.22%
Perf 3Y
-71.81%
Perf 5Y
-90.85%
Perf 10Y
-
Prev Close
1.17
Price
1.17
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$4.11
Implied Upside
+251.3%
Analysts7incl. previous ratings
Rating Distribution5 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 11, 2025Downgrade
BBTIG Research
Buy → Neutral
Aug 07, 2025Downgrade
WWilliam Blair
Outperform → Mkt Perform
Jul 22, 2025Initiated
SStephens
Overweight$6+412.8%
Nov 29, 2023Initiated
CCraig Hallum
Buy$7+498.3%
Oct 15, 2021Resumed
CCowen
Outperform
Aug 24, 2021Initiated
WWilliam Blair
Outperform
Aug 24, 2021Initiated
WWedbush
Outperform$36+2,976.9%
Aug 24, 2021Initiated
SF logoSStifel
Buy$18+1,438.5%
Aug 24, 2021Initiated
SStephens
Overweight$19+1,523.9%
Aug 24, 2021Initiated
CCowen
Outperform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Swirsky Douglas JCHIEF FINANCIAL OFFICERMar 17 '26Sale0.8110,1428,266151,669Mar 19 04:05 PM
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.
PresidentMr. Maher Masoud
Chief Financial OfficerMr. Parmeet Ahuja
Chief Operations OfficerMr. Jay Gelfman
Senior Vice President of Global SalesMs. Ana-Paula Martins Fernandes
Chief Corporate Development OfficerMr. Sidharth Kapileshwar